ArticleJournal of clinical pharmacology2016

A phase-1, open-label, single-dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment.

Denes Csonka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.